Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 10/20 | 0.71 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.71 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.71 |
| ▸ | GABRB2 | P47870 | 8/20 | 0.71 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.69 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.69 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.69 |
| ▸ | CCKBR | P32239 | 2/20 | 0.69 |
| ▸ | GABRP | O00591 | 2/20 | 0.59 |
| ▸ | GABRD | O14764 | 2/20 | 0.59 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.59 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.59 |
| ▸ | GABRE | P78334 | 2/20 | 0.59 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.59 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.59 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.59 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486030 | 0.88 | GABRA1 (0.77) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL13352307 | 0.87 | GABRA1 (0.73) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL29395499 | 0.86 | GABRA1 (0.72) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL11772593 | 0.86 | GABRA1 (0.71) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL11769435 | 0.86 | GABRA1 (0.72) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL11067351 | 0.86 | GABRA1 (0.71) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL5037299 | 0.85 | GABRA1 (0.70) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL7722307 | 0.84 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| SCHEMBL14212131 | 0.83 | GABRA1 (0.79) | GABRA1GABRA5GABRA2GABRB2GABRA3 | |
| Ro-054520 SCHEMBL11858895 | 0.82 | GABRA1 (0.70) | GABRA1GABRA5GABRA2GABRB2GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | COOK JAMES M | 2010-01-07 | — | — | US | disclosed |
| US-7618958-B2 | Convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnosis; Ethyl 8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-0616532-A4 | USE OF PERIPHERAL-TYPE BENZODIAZEPINE SITES FOR TREATMENT OF CNS TRAUMA OR DISEASE. | COCENSYS INC (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0616532-A1 | USE OF PERIPHERAL-TYPE BENZODIAZEPINE SITES FOR TREATMENT OF CNS TRAUMA OR DISEASE | COCENSYS, INC. (US) | 1994-09-28 | — | — | EP | disclosed |
| WO-1993011771-A1 | USE OF PERIPHERAL-TYPE BENZODIAZEPINE SITES FOR TREATMENT OF CNS TRAUMA OR DISEASE | COCENSYS, INC. (US) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA2 2/4885 |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA2 2/4885 |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | GABRA1 3/4885GABRA5 6/4885GABRA2 2/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | GABRA1 5/4885GABRA5 6/4885GABRA2 4/4885 |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | CHRNA6, GABRA6, CHRNA5 | GABRA1 7/4885GABRA5 4/4885GABRA2 14/4885 |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | GABRA5, GABRA6, GABRA2 | GABRA1 4/4885GABRA5 1/4885GABRA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.